• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    9/5/25 4:15:38 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    false 0001269026 0001269026 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): September 4, 2025

     

    SINTX Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33624   84-1375299

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1885 West 2100 South

    Salt Lake City, UT

      84119
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (801) 839-3500

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
    Common Stock, par value $0.01 per share   SINT   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (c) Appointment of Principal Financial Officer

     

    On September 4, 2025, the Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Kevin Trask as Chief Financial Officer for the Company. In connection with Mr. Trask’s appointment, his annual salary was increased to $300,000 per annum, he is now eligible for a bonus of up to 35% of his salary payable at the discretion of the Board of Directors, and he received an award of 20,000 restricted stock units, 20% of which were immediately vested with the remainder vesting at the rate of 20% every six months thereafter until fully vested.

     

    Prior to being appointed as the Company’s Chief Financial Officer, Mr. Trask, age 40, served as the Company’s Corporate Controller from May 2025 to September 2025. From May 2024 to May 2025, he served as Corporate Controller at USANA Health Sciences, Inc., a global publicly traded company. From October 2022 to May 2024, Mr. Trask served as the Head of Finance and Accounting at an early-stage private consumer goods company. From June 2021 to October 2022, Mr. Trask served as the Director of Accounting at Quotient Technologies, Inc, a publicly traded company. Prior to Quotient, Mr. Trask held multiple, progressive accounting and finance management positions at global publicly traded companies. He began his career in public accounting, providing assurance services to both large and small private and public companies. Mr. Trask holds a B.S. in Accounting from California State Polytechnic University and is an actively licensed CPA.

     

    There are no family relationships between Mr. Trask and any director or other executive officer of the Company. There are no transactions to which the Company was or is a participant and in which Mr. Trask has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

     

    There are no arrangements or understandings between Mr. Trask and any other person pursuant to which he was selected as an officer of the Company.

     

    (e) Compensatory Arrangements of Certain Officers

     

    On September 4, 2025, at the 2025 Annual Meeting of Stockholders of the Company, along with other items discussed in Item 5.07 below, the Company’s stockholders approved the 2025 Equity Incentive Plan (the “Plan”). The Plan was previously approved by the Company’s Board of Directors, subject to stockholder approval.

     

    The material features of the Plan are described on pages 30 through 35 of the Company’s definitive proxy statement, filed with the U.S. Securities and Exchange Commission on July 31, 2025 (the “Proxy Statement”), which description is incorporated by reference herein. Additionally, the full text of the Plan is appended as Appendix A to the Proxy Statement and incorporated by reference herein. The description of the Plan in the Proxy Statement and the foregoing disclosure under Item 5.02(e) of this Current Report on Form 8-K are qualified in their entirety by reference to the full text of the Plan.

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On September 4, 2025, SINTX Technologies, Inc. held its 2025 annual meeting of stockholders at which the following matters were voted on:

     

    Proposal No. 1: Election of Directors. The Company’s stockholders elected for a three-year term two persons nominated for election as Class II directors. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors:

     

    Nominee  Votes For   Votes Withheld   Broker Non-vote   Abstain 
    Robert Mitchell   879,648    12,298    637,032    - 
    Chris Lyons   879,749    12,197    637,032      

     

    Proposal No. 2: A proposal to ratify the Audit Committee’s appointment of Tanner LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2025. This proposal was ratified.

     

    For   Against   Abstain   Broker Non-vote 
    1,488,908    33,019    7,051    - 

     

    Proposal No. 3: A proposal to adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation.” This proposal was adopted.

     

    For   Against   Abstain   Broker Non-vote 
    847,475    40,089    4,382    637,032 

     

    Proposal No. 4: A proposal to approve adoption of the 2025 Equity Incentive Plan. This proposal was approved.

     

    For   Against   Abstain   Broker Non-vote 
    813,349    74,329    4,268    637,032 

     

    Proposal No. 5: A proposal to approve one or more adjournments of the annual meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the meeting to adopt one or more of the foregoing proposals. This proposal was approved.

     

    For   Against   Abstain   Broker Non-vote 
    1,414,413    107,270    7,295    - 

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   SINTX Technologies, Inc. 2025 Equity Incentive Plan (incorporated by reference to Appendix A to the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 31, 2025).
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SINTX TECHNOLOGIES, INC.
       
    Date: September 5, 2025 /s/ Kevin Ontiveros
      Kevin Ontiveros
      Chief Legal Officer

     

     

     

    Get the next $SINT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025

    SALT LAKE CITY, Utah, Sept. 09, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that it has been invited to present at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The Company's presentation is scheduled for Tuesday, September 9, 2025. "This event provides an important opportunity to share our objectives, highlight our progress, and engage directly with the institutional investor community," said Eric Olson, Chairman and

    9/9/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

    Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, "Antipathogenic Fibrous Materials." The patent secures broad protection for SINTX's proprietary silicon nitride–based antipathogen platform. This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neu

    9/8/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition

    Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at www.sec.gov. The business update highlights meaningful progress from the Company's recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy

    8/15/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $185,000 worth of shares (50,000 units at $3.70), increasing direct ownership by 357% to 64,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    President and CEO Olson Eric K. bought $37,470 worth of shares (10,475 units at $3.58), increasing direct ownership by 72% to 24,975 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/25/25 5:14:09 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    10/3/25 5:07:49 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by SiNtx Technologies Inc.

    424B5 - Sintx Technologies, Inc. (0001269026) (Filer)

    10/3/25 5:05:33 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by SiNtx Technologies Inc.

    S-8 - Sintx Technologies, Inc. (0001269026) (Filer)

    9/30/25 4:56:34 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    9/5/25 5:01:30 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    New insider Trask Kevin claimed ownership of 4,376 shares (SEC Form 3)

    3 - Sintx Technologies, Inc. (0001269026) (Issuer)

    9/5/25 5:00:28 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $10,756 worth of shares (3,000 units at $3.59) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    8/27/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

    SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

    3/25/22 5:41:39 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care